 NEW YORK, July 27, 2021 PRNewswire -- BrainStorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice GMP approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company at the Tel Aviv Sourasky Medical Center Sourasky Hospital in Tel Aviv, Israel. The GMP approval confirms that these cleanrooms are compliant with Israeli GMPs, which are aligned with European Union EU GMPs, and more than doubles the Companys capacity to manufacture and ship NurOwn into the EU and local Israeli markets. 